ArticleJournal of personalized medicine2022

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy.

Jiayi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.